Pancreatic enzyme replacement therapy in advanced adenocarcinoma of the pancreas improved overall survival: a retrospective, single institution study
The Oncologist · 2025
DOI: 10.1093/oncolo/oyaf014 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, 2025. Verfasst von Vincent J Picozzi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Virginia Mason Hospital and Medical Center, Seattle, WA 98111, United States. Hauptthemen laut MEDLINE: Enzyme Replacement Therapy, Pancreatic Neoplasms, Adenocarcinoma, Carcinoma, Pancreatic Ductal. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AbbVie.
Abstract (Originalsprache)
Background
Weight loss and exocrine pancreatic insufficiency are common in advanced pancreatic ductal adenocarcinoma (PDAC) and are associated with adverse outcomes. However, there is limited evidence on the impact of pancreatic enzyme replacement therapy (PERT) in patients with advanced PDAC. Patients and methods We retrospectively studied 501 patients with advanced PDAC and exocrine pancreatic insufficiency from the Virginia Mason Pancreas Cancer Program Data Resource treated between 2010 and 2019 with first-line chemotherapy. Clinical outcomes were compared between those who received PERT and those who did not at 8 weeks after chemotherapy start.
Results
In total 188 (38%) patients received PERT; 313 patients (62%) did not. PERT patients experienced less weight loss (–1.5 vs –2.5 kg, P = .04), less decline in the prognostic nutrition index −1.9 vs −3.0, P = .01), and a greater reduction in the additive score of the Patient-Generated Subjective Global Assessment (–8.4 vs –-6.0, P = .02). Importantly, median (95% CI) overall survival (OS) was significantly longer in the PERT vs non-PERT group (17.1 months vs 12.5 months, respectively P = .001), and the adjusted hazards ratio indicated superior median OS in patients prescribed PERT (HR = 0.73, P < .001).
Conclusions
Our findings suggest that treatment of exocrine pancreatic insufficiency (EPI) in advanced PDAC is associated with improvements in nutrition and overall survival.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Virginia Mason Hospital and Medical Center, Seattle, WA 98111, United States.
- Benaroya Research Institute, Seattle, WA 98101, United States.
- Data and Statistical Sciences, AbbVie Inc., North Chicago, IL 60064, United States.
- US Medical Affairs, AbbVie Inc., Mettawa, IL 60045, United States.
ORCID-Profile: Vincent J Picozzi
Förderung
- AbbVie
Zitieren
APA
Picozzi, V. J., Mandelson, M. T., Najjar, A., Li, M., Harb, D. E., & Kort, J. J. (2025). Pancreatic enzyme replacement therapy in advanced adenocarcinoma of the pancreas improved overall survival: a retrospective, single institution study. The Oncologist. https://doi.org/10.1093/oncolo/oyaf014
Vancouver
Picozzi VJ, Mandelson MT, Najjar A, Li M, Harb DE, Kort JJ. Pancreatic enzyme replacement therapy in advanced adenocarcinoma of the pancreas improved overall survival: a retrospective, single institution study. The Oncologist. 2025. doi:10.1093/oncolo/oyaf014
BibTeX
@article{Picozzi2025,
author = {Picozzi, Vincent J and Mandelson, Margaret T and Najjar, Anas and Li, Moming and Harb, Diala E and Kort, Jens J},
title = {Pancreatic enzyme replacement therapy in advanced adenocarcinoma of the pancreas improved overall survival: a retrospective, single institution study},
journal = {The Oncologist},
year = {2025},
doi = {10.1093/oncolo/oyaf014}
}
EUVIMED